Previous Close | 67.31 |
Open | 67.35 |
Bid | 66.92 x 400 |
Ask | 66.96 x 400 |
Day's Range | 66.89 - 67.54 |
52 Week Range | 66.89 - 87.87 |
Volume | |
Avg. Volume | 7,420,538 |
Market Cap | 83.46B |
Beta (5Y Monthly) | 0.20 |
PE Ratio (TTM) | 14.87 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 3.08 (4.60%) |
Ex-Dividend Date | Mar 14, 2024 |
1y Target Est | N/A |
Xilio (XLO) rallies 79.8% in a month on an exclusive global licensing agreement with Gilead Sciences to develop XTX301 for advanced solid tumors.
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
In the most recent trading session, Gilead Sciences (GILD) closed at $68.07, indicating a -0.84% shift from the previous trading day.